RSS Feeds
Search

PR Newswire

Elsevier's Journal of Diabetes and its Complications Announces New Editorial Team and Expansion

<img src="http://pharmalicensing.com/public/img/prnewswire.gif" alt="PR Newswire" align="center" class="nitflogo" />— OXFORD, England, April 2, 2012

OXFORD, England, April 2, 2012 /PRNewswire/ --

Global diabetes epidemic increases demand for high-quality research

publications

Elsevier's Journal of Diabetes and its Complications http://www.jdcjournal.com ] is pleased to announce the appointment of a high-profile senior editorial team who will oversee a significant increase in the number of quality papers published in 2012. The increasing prevalence and impact of diabetes worldwide means that means that the journal has to grow in quality and size to meet the demands of clinicians at the forefront of the epidemic.

The new Editor-in-Chief is Vivian A. Fonseca, MD, FRCP, Professor of Medicine, Tullis-Tulane Alumni Chair in Diabetes, and Chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana. Professor Fonseca is also President for Science and Medicine at the American Diabetes Association.

On his new appointment, Professor Fonseca commented, "We are facing a major international public health crisis with the increase in diabetes. Dissemination of high-quality research will help stem this epidemic. I am delighted to have the opportunity to play a significant role in this aspect as journal editor. Our aim is to publish high-quality articles covering all aspects of diabetes, with an emphasis on translating research into clinical practice."

Drs. Stefano Del Prato (Pisa, Italy) and Steven Kahn (Seattle, USA) have joined the journal as Associate Editors. Drs. Del Prato and Kahn are internationally recognized figures in the diabetes community with research interests spanning basic science through to clinical.

Andrew Miller, Executive Publisher of Journal of Diabetes and its Complications, stated, "Elsevier is delighted to appoint a senior editorial team of such experience and caliber. Diabetes is a huge and growing challenge and the journal is expanding to address the needs of researchers and clinicians worldwide."

About the Journal of Diabetes and its Complications

The primary aim of Journal of Diabetes and Its Complications http://www.jdcjournal.com ] is to provide usable information for practitioners caring for patients with diabetes who are at risk of developing further complications. The journal also acts as a forum for the dissemination of experimental work that may inform current thinking in the field of diabetes research.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet http://www.thelancet.com ] and Cell http://www.cell.com ], and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect http://www.sciencedirect.com ], SciVerse Scopus http://www.scopus.com ], Reaxys http://www.reaxys.com ], MD Consult http://www.mdconsult.com ] and Mosby's Nursing Suite http://www.confidenceconnected.com ], which enhance the productivity of science and health professionals, and the SciVal suite http://www.scival.com ] and MEDai's Pinpoint Review http://www.medai.com ], which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier http://www.elsevier.com ] employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC http://www.reedelsevier.com ], a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact Andrew Miller Elsevier +44-1865-843-823 andrew.miller@elsevier.com

Related Pharmalicensing company profiles

Related news

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us